Presentation of Case

A 44-year-old African man was referred for evaluation of progressive lower-extremity weakness and gait impairment.

Four months before presentation, he developed tingling in both feet. Over the following weeks, burning discomfort appeared in the legs, accompanied by progressive weakness. Walking became increasingly difficult. Family members observed worsening balance, increasing fatigue, and frequent stumbling. Activities that had once been routine became progressively challenging.

The progression was gradual rather than abrupt.

There was no history of fever, trauma, bowel dysfunction, bladder dysfunction, diplopia, dysphagia, fluctuating weakness, or visual symptoms.

Notably, there was no history suggestive of acute organophosphate poisoning. He had never experienced excessive salivation, lacrimation, diarrhea, vomiting, bronchorrhea, respiratory failure, or generalized fasciculations.

The occupational history was striking.

For nine years, he had worked as a pesticide applicator handling chlorpyrifos, malathion, and diazinon. He commonly sprayed pesticides for 6–9 hours daily, often in poorly ventilated environments and frequently without personal protective equipment.

According to family members, symptoms had evolved gradually over several years. During the first five years of exposure, he experienced intermittent headaches, dizziness, fatigue, and distal paresthesias. During years six through eight, muscle cramps, burning leg pain, and progressive weakness developed. By year nine, gait dysfunction and mild cognitive complaints had become apparent.

The central question becomes:

What neurologic process could explain progressive gait failure, sensory symptoms, and weakness in a middle-aged agricultural worker with years of pesticide exposure?

Initial Clinical Localization

Before considering specific diagnoses, localization is essential.

The neurologic examination demonstrated:

• Bilateral lower-extremity weakness
• Distal sensory loss
• Loss of vibration sensation
• Reduced pinprick sensation
• Foot drop
• Calf muscle atrophy
• Absent lower-extremity reflexes
• Marked gait dysfunction

The combination of motor and sensory deficits immediately localizes the process to the peripheral nervous system.

Several observations deserve emphasis.

The presence of sensory symptoms argues strongly against a pure motor disorder.

Motor neuron disease becomes less likely because ALS typically spares sensory pathways.

Neuromuscular junction disorders such as myasthenia gravis do not produce sensory loss.

Likewise, primary myopathies do not explain neuropathic pain, absent reflexes, or distal sensory deficits.

At this stage, the syndrome is most consistent with:

A chronic length-dependent sensorimotor polyneuropathy.

Differential Diagnosis

Once localization has been established, the differential diagnosis narrows substantially.

Diabetic Polyneuropathy

Diabetes remains the most common cause of neuropathy worldwide.

Supporting features include distal sensory symptoms and progressive weakness.

However, there was no history of diabetes, laboratory studies were normal, and the severity of motor dysfunction appeared disproportionate to typical diabetic neuropathy.

This diagnosis became unlikely.

Vitamin B12 Deficiency

Vitamin B12 deficiency can produce gait impairment, sensory loss, and weakness.

However, vitamin levels were normal, and the clinical pattern did not strongly suggest a posterior column syndrome.

This diagnosis was effectively excluded.

Chronic Inflammatory Demyelinating Polyneuropathy

CIDP deserves consideration whenever weakness evolves over months.

Supporting features include:

• Progressive course
• Motor and sensory deficits

However, several observations argue against CIDP:

• Strong toxic exposure history
• Lack of a relapsing course
• Absence of other inflammatory features

CIDP remained possible but was not favored.

Hereditary Neuropathy

Hereditary neuropathies can produce distal weakness, sensory loss, and foot drop.

However:

• There was no family history.
• Symptom onset occurred in adulthood.
• The temporal association with occupational exposure was compelling.

This diagnosis became less likely.

Motor Neuron Disease

Progressive weakness always raises concern for ALS.

Yet several findings argue strongly against ALS:

• Prominent sensory symptoms
• Sensory examination abnormalities
• Neuropathic pain
• Absent reflexes

Motor neuron disease became unlikely.

Toxic Neuropathy

At this point, toxic neuropathy emerged as the leading consideration.

The reasons were straightforward:

1. Nine years of pesticide exposure.
2. Progressive neurologic decline.
3. Lack of alternative explanations.
4. Strong temporal relationship between exposure and symptom evolution.

Yet one challenge remained.

Most clinicians associate organophosphate toxicity with acute cholinergic poisoning.

This patient had never experienced a cholinergic crisis.

Could chronic low-level exposure still produce neurologic injury?

The Diagnostic Pivot

The answer lies in recognizing that organophosphates produce more than one neurologic syndrome.

Most physicians are familiar with acute cholinergic toxicity resulting from acetylcholinesterase inhibition.

This syndrome presents with:

• Salivation
• Lacrimation
• Urination
• Diarrhea
• Bronchorrhea
• Fasciculations

The patient never experienced these manifestations.

However, organophosphate exposure may also produce:

Intermediate Syndrome

and

Organophosphate-Induced Delayed Neuropathy (OPIDN)

Unlike acute poisoning, OPIDN may emerge days, weeks, months, or even after years of cumulative exposure.

At this point, OPIDN became the leading diagnostic hypothesis.

The next task was to determine whether objective testing supported that conclusion.

Electrophysiologic Confirmation

Nerve conduction studies proved decisive.

The studies demonstrated:

• Reduced compound muscle action potential amplitudes
• Reduced sensory nerve action potential amplitudes
• Slowed conduction velocities
• Prolonged distal latencies

These findings indicate a mixed pattern of:

• Axonal degeneration
• Demyelinating injury

This is a critical observation.

The electrophysiology established the presence of a diffuse sensorimotor polyneuropathy and excluded many competing diagnoses.

The studies argued against:

• Functional neurologic disorder
• Neuromuscular junction disease
• Primary myopathy
• Isolated motor neuron disease

Instead, they provided objective evidence supporting a severe toxic neuropathy.

Laboratory Interpretation

Additional support came from laboratory studies.

Serum cholinesterase activity was markedly reduced at 1,800 U/L.

Normal values range from approximately 5,320–12,920 U/L.

This finding confirms significant organophosphate exposure.

However, cholinesterase levels alone do not establish OPIDN.

Some exposed individuals never develop neuropathy, while some patients may have improving enzyme levels by the time neurologic symptoms emerge.

The diagnosis therefore depends on integration of:

• Exposure history
• Clinical syndrome
• Neurologic examination
• Electrophysiology
• Laboratory findings

No single test is diagnostic.

Reconciling the Presence of Spasticity

One aspect of the examination deserves special attention.

The patient demonstrated spasticity.

At first glance, this finding seems inconsistent with peripheral neuropathy.

Peripheral neuropathies generally produce:

• Hypotonia
• Hyporeflexia
• Flaccid weakness

Spasticity suggests upper motor neuron dysfunction.

The explanation lies in the biology of OPIDN.

Unlike many toxic neuropathies, OPIDN can affect both peripheral nerves and central motor pathways.

Damage to corticospinal tracts may coexist with severe peripheral neuropathy.

This dual involvement explains why spasticity and absent reflexes may appear in the same patient.

Rather than arguing against the diagnosis, the presence of spasticity actually supports it.

Neuroimaging Discussion

MRI demonstrated mild spinal cord atrophy.

This finding is notable primarily because of what it excludes.

There was no evidence of:

• Compressive myelopathy
• Demyelinating disease
• Tumor
• Structural cord lesion

The MRI therefore serves primarily to exclude alternative diagnoses.

The dominant pathology remains within the peripheral nervous system.

This illustrates an important neurologic principle:

Imaging must always be interpreted in the context of clinical localization.

Pathophysiology

The pathophysiology of OPIDN differs fundamentally from acute cholinergic toxicity.

Acute poisoning results from acetylcholinesterase inhibition.

Delayed neuropathy is primarily associated with inhibition of:

Neuropathy Target Esterase (NTE)

NTE is important for maintaining neuronal membrane integrity and axonal function.

When NTE is inhibited:

1. Axonal transport becomes impaired.
2. Distal axonal degeneration develops.
3. Myelin injury occurs.
4. Neuroinflammation is triggered.
5. Progressive neurologic dysfunction follows.

The process resembles a dying-back axonopathy.

Because the longest axons are most vulnerable, symptoms begin distally in the feet and ascend gradually.

Additional mechanisms include:

• Oxidative stress
• Mitochondrial dysfunction
• Calcium dysregulation
• Neuroinflammatory signaling

The result is a progressive sensorimotor neuropathy with possible corticospinal tract involvement.

Cognitive Biases and Diagnostic Pitfalls

This case illustrates several important cognitive biases.

Availability Bias

Most clinicians immediately recall acute cholinergic poisoning.

Few think of delayed neuropathy.

As a result, OPIDN may be overlooked.

Anchoring Bias

Clinicians may anchor on common diagnoses such as:

• Diabetes
• Lumbar spinal stenosis
• Vitamin deficiency

and fail to adequately weigh the exposure history.

Premature Closure

Routine laboratory studies were largely normal.

Stopping the evaluation at that point would have missed the diagnosis.

Search Satisficing

The mild MRI abnormality could easily have become a false endpoint.

However, it did not adequately explain the clinical syndrome.

Continued investigation was essential.

Final Diagnosis

Organophosphate-Induced Delayed Neuropathy (OPIDN) caused by nine years of chronic occupational exposure to chlorpyrifos, malathion, and diazinon.

Discussion

This case highlights one of the most underrecognized toxic neurologic syndromes in clinical practice.

Organophosphate exposure remains common worldwide, particularly among agricultural workers.

Most educational efforts focus on acute poisoning.

Far less attention is devoted to delayed neurologic consequences.

Consequently, many patients undergo prolonged evaluations before the correct diagnosis is recognized.

The present case demonstrates the classic features of OPIDN:

• Chronic exposure
• Progressive sensory symptoms
• Distal weakness
• Gait dysfunction
• Reduced cholinesterase activity
• Electrophysiologic evidence of neuropathy

The diagnosis ultimately emerged through synthesis of multiple lines of evidence.

Most importantly, it emerged through careful history-taking.

The occupational history provided the crucial clue.

As Sir William Osler observed more than a century ago:

Listen to the patient; they are telling you the diagnosis.

Clinical Pearls

• OPIDN may occur without a preceding cholinergic crisis.
• A detailed occupational history is essential in unexplained neuropathy.
• Long-term pesticide exposure should prompt consideration of toxic neuropathy.
• Nerve conduction studies are central to diagnosis.
• Reduced cholinesterase activity supports exposure but is not independently diagnostic.
• OPIDN may affect both peripheral and central motor pathways.
• MRI is often more useful for excluding alternative diagnoses than confirming OPIDN.
• Prevention remains the most effective intervention.

Clinical Take-Home Message

When progressive gait impairment, distal sensory loss, and lower-extremity weakness occur in an agricultural worker, clinicians must look beyond common neuropathies and carefully investigate occupational exposures. Organophosphate-induced delayed neuropathy can develop after years of cumulative exposure, even in the absence of acute poisoning. Recognition depends on meticulous history-taking, thoughtful localization, and integration of electrophysiologic and laboratory findings.

Board Review Questions

Question 1

A 44-year-old pesticide applicator develops progressive foot drop, distal sensory loss, and gait impairment after years of organophosphate exposure. Which diagnosis is most likely?

A. CIDP
B. ALS
C. OPIDN
D. Myasthenia gravis
E. Lambert–Eaton syndrome

Answer

C. OPIDN

Explanation

The combination of prolonged organophosphate exposure, progressive sensorimotor neuropathy, reduced cholinesterase activity, and electrophysiologic evidence of axonal degeneration strongly supports OPIDN. Sensory symptoms effectively exclude ALS and neuromuscular junction disorders.

Question 2

Which enzyme is most closely linked to the pathogenesis of OPIDN?

A. Acetylcholinesterase
B. Monoamine oxidase
C. Neuropathy target esterase
D. Dopamine β-hydroxylase
E. Tyrosine hydroxylase

Answer

C. Neuropathy Target Esterase

Explanation

Although acetylcholinesterase inhibition causes acute cholinergic toxicity, delayed neuropathy is primarily associated with inhibition of neuropathy target esterase (NTE), leading to distal axonal degeneration and progressive neurologic dysfunction.

Question 3

Which electrophysiologic pattern is most characteristic of OPIDN?

A. Normal studies
B. Pure demyelination
C. Pure neuromuscular junction dysfunction
D. Mixed axonal and demyelinating sensorimotor neuropathy
E. Primary myopathic changes

Answer

D. Mixed Axonal and Demyelinating Sensorimotor Neuropathy

Explanation

Reduced amplitudes, slowed conduction velocities, and prolonged distal latencies indicate both axonal degeneration and demyelinating injury, a pattern commonly observed in severe toxic neuropathies.

Question 4

Which cognitive bias most commonly delays recognition of OPIDN?

A. Hawthorne effect
B. Availability bias
C. Spectrum bias
D. Gambler's fallacy
E. Observer bias

Answer

B. Availability Bias

Explanation

Clinicians readily recall dramatic cholinergic poisoning but often fail to consider delayed neuropathy because it is less commonly encountered and less memorable.

Question 5

Which intervention remains the cornerstone of management?

A. Emergent plasmapheresis
B. Long-term IVIG
C. Deep brain stimulation
D. Supportive rehabilitation and prevention of further exposure
E. Surgical decompression

Answer

D. Supportive Rehabilitation and Prevention of Further Exposure

Explanation

No disease-specific antidote exists for OPIDN. Management focuses on eliminating further exposure, physical therapy, gait rehabilitation, treatment of neuropathic pain, and optimization of functional recovery.

Journal of Medical Case Reports is the world's first international, PubMed-listed medical journal devoted to publishing case reports from all medical disciplines and will consider any original case report that expands the field of general medical knowledge, and original research relating to case reports. The journal is open access, and strongly endorses the CARE guidelines for case reports, requiring authors to submit populated CARE checklists with submissions to improve transparency in reporting.